Skip to main content
SpringerLink
Log in

Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers

  • Original Investigations
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

The serotonin agonist m-chlorophenylpiperazine (m-CPP) had greater anxiogenic and other mood and cognitive effects when administered intravenously (0.1 mg/kg) rather than orally (0.5 mg/kg) to healthy subjects. Nonetheless, similar elevations in peak plasma cortisol and prolactin concentrations were obtained with the two dosage regimens, and temperature elevations were greater after oral m-CPP. Plateau phase plasma concentrations of m-CPP at the times of the maximum neuroendocrine responses to intravenous and oral m-CPP were similar. Since all rodent and nonhuman primate studies have used parenterally administered m-CPP, and previous clinical investigations using intravenous rather than oral m-CPP have yielded somewhat discrepant results, our normative data should be useful for comparing results, our normative data should be useful for comparing results across different human studies and across species.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Aloi JA, Insel TR, Mueller EA, Murphy DL (1984) Neuroendocrine and behavioral effects of m-chlorophenylpiperazine administration in rhesus monkeys. Life Sci 34:1325–1331

    Google Scholar 

  • American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, 3rd ed. revised. American Psychiatric Association Press, Washington, DC

    Google Scholar 

  • Aulakh CS, Cohen RM, Hill JL, Murphy DL, Zohar J (1987) Long-term imipramine treatment enhances locomotor and food intake suppressant effects of m-chlorophenylpiperazine in rats. Br J Pharmacol 91:747–752

    Google Scholar 

  • Aulakh CS, Wozniak KM, Haas M, Hill JL, Zohar J, Murphy DL (1988) Food intake, neuroendocrine and temperature effects of 8-OHDPAT in the rat. Eur J Pharmacol 146:253–259

    Google Scholar 

  • Bagdy G, Szemeredi K, Zukowska-Grojec Z, Hill J, Murphy DL (1987) m-Chlorophenylpiperazine increases blood pressure and heart rate in pithed and conscious rats. Life Sci 41:775–782

    Google Scholar 

  • Blackshear MA, Martin LL, Sanders-Bush E (1986) Adaptive changes in the 5-HT2 binding site after chronic administration of agonists and antagonists. Neuropharmacology 25:1267–1271

    Google Scholar 

  • Brewerton TD, Murphy DL, Mueller EA, Jimerson DC (1988) Induction of migraine-like headaches by the serotonin agonist m-chlorophenylpiperazine. Clin Pharmacol Ther 43:605–609

    Google Scholar 

  • Caccia S, Ballabio M, Samanin R, Zanini MG, Garattini S (1981) (-)-m-Chlorophenyl-piperazine, a central 5-hydroxytryptamine agonist, is a metabolite of trazodone. J Pharm Pharmacol 33:477–478

    Google Scholar 

  • Caccia S, Fong MH, Garattinis V, Zanini MG (1982) Plasma concentrations of trazodone and 1-(3-chlorophenyl) piperazine in man after a single oral dose of trazadone. J Pharm Pharmacol 34:605–606

    Google Scholar 

  • Charney DS, Woods SW, Goodman WK, Heninger GR (1987) Serotonin function in anxiety: II. Effects of the serotonin agonist m-CPP in panic disorder patients and healthy subjects. Psychopharmacology 92:14–24

    Google Scholar 

  • Charney DS, Goodman WK, Price LH, Rasmussen SA, Woods SW, Heninger GR (1988) Serotonin function in obsessive compulsive disorder. Arch Gen Psychiatry 45:177–188

    Google Scholar 

  • Chopin P, Briley M (1987) Animal models of anxiety: the effect of compounds that modify 5-HT neurotransmission. TIPS 8:383–388

    Google Scholar 

  • Cohen ML, Fuller RW (1983) Antagonism of vascular serotonin receptors by m-chlorophenylpiperazine and m-trifluoromethyl-phenylpiperazine. Life Sci 32:711–718

    Google Scholar 

  • Cohen RM, Aulakh CS, Murphy DL (1983) Long-term clorgyline treatment antagonizes the eating and motor function responses to m-chlorophenylpiperazine. Eur J Pharmacol 94:175–179

    Google Scholar 

  • Conn PJ, Sanders-Bush E (1987) Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1c) receptors. J Pharmacol Exp Ther 242:552–557

    Google Scholar 

  • Cunningham KA, Appel JB (1986) Possible 5-hydroxytryptamine1 (5-HT1) receptor involvement in the stimulus properties of 1-(m-trifluoromethylphenyl)piperazine (TFMPP). J Pharmacol Exp Ther 237:369–377

    Google Scholar 

  • Eison MS (1984) Use of animal models: toward anxioselective drugs. Psychopathology [Suppl 1] 17:37–44

    Google Scholar 

  • Engel G, Gothert M, Hoyer D, Schlicker E, Hillenbrand K (1986) Identity of inhibitory presynaptic 5-hydroxytryptamine (5-HT) autoreceptors in the rat brain cortex with 5-HT1B binding sites. Naunyn-Schmiedebergs Arch Pharmacol 332:1–7

    Google Scholar 

  • Fuller RW, Snoddy HD, Mason NR, Owen JE (1981) Disposition and pharmacological effects of m-chlorophenylpiperazine in rats. Neuropharmacology 20:155–162

    Google Scholar 

  • Goa KL, Ward A (1986) Buspirone: a preliminary review of its pharmacological properties and therapeutic efficacy as a anxiolytic. Drugs 32:114–129

    Google Scholar 

  • Hamik A, Peroutka SJ (1987) 1-(m-Chlorophenyl) piperazine (m-CPP) interactions with neurotransmitter receptors in human brain. Soc Neurosci Abstr 13:1237

    Google Scholar 

  • Invernizzi R, Cotecchia S, De Blasi A, Mennini T, Patuccini R, Samanin R (1981) Effects of m-chlorophenylpiperazine on receptor binding and brain metabolism of monoamines in rats. Neurochem Int 3:239–244

    Google Scholar 

  • Ireland SJ, Tyers MB (1987) Pharmacological characterization of 5-hydroxytryptamine-induced depolarization of the rat isolated vagus nerve. Br J Pharmacol 90:229–238

    Google Scholar 

  • Kahn RS, Asnis GM, Wetzler S, van Praag HM (1989) Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder. Psychopharmacology (in press)

  • van Kammen DP, Murphy DL (1975) Attenuation of the euphoriant and activating effects of d-and l-amphetamine by lithium carbonate treatment. Psychopharmacologia 44:215–224

    Google Scholar 

  • Kennett GA, Curzon G (1988) Evidence that m-CPP may have behavioural effects mediated by central 5-HT1C receptors. Br J Pharmacol 94:137–147

    Google Scholar 

  • Lucki I, Frazer A (1985) Changes in behavior associated with serotonin receptors following repeated treatment with antidepressant drugs. In: Seiden LS, Balster RL (eds) Behavioral pharmacology: the current status. Liss, New York, pp 339–357

    Google Scholar 

  • Maj J, Lewandowska A (1980) Central serotoninmimetic action of phenylpiperazines. Pol J Pharmacol Pharm 32:495–504

    Google Scholar 

  • Maj J, Palider W, Rawlow A (1979) Trazodone, a central serotonin antagonist and agonist. J Neural Transm 44:237–248

    Google Scholar 

  • Mansbach RS, Barrett JE (1987) Discriminative stimulus properties of buspirone in the pigeon. J Pharmacol Exp Ther 240:364–369

    Google Scholar 

  • McCall RB, Patel BN, Harris LT (1987) Effects of serotonin1 and serotonin2 receptor agonists and antagonists on blood pressure, heart rate and sympathetic nerve activity. J Pharmacol Exp Ther 242:1152–1159

    Google Scholar 

  • McKenney JD, Glennon RA (1986) TFMPP may produce its stimulus effects via a 5-HT1B mechanism. Pharmacol Biochem Behav 24:43–47

    Google Scholar 

  • Meert TF, Colpaert FC (1986) The effects of agonists and antagonists at putative 5-HT receptor subtypes in the shock-probe conflict procedure. Psychopharmacology 89:S 23

    Google Scholar 

  • Mellow AM, Lawlor BA, Sunderland T, Mueller EA, Molchan SE, Murphy DL (1988) A pilot clinical trial of m-CPP in depression. Annual Meeting of the American Psychiatric Association, New Research Abstracts, Montreal, May 1988

  • Meltzer HY, Lowy MT (1987) The serotonin hypothesis of depression in psychopharmacology. In: Meltzer HY (ed) Neuropsychopharmacology: the third generation of progress. Raven Press, New York, pp 513–526

    Google Scholar 

  • Mueller EA, Murphy DL, Sunderland T (1985a) Neuroendocrine effects of m-chlorophenylpiperazine, a serotonin agonist, in humans. J Clin Endocrinol Metab 61:1179–1184

    Google Scholar 

  • Mueller EA, Murphy DL, Sunderland T, Jones J (1985b) A new postsynaptic serotonin receptor agonist suitable for studies in humans. Psychopharmacol Bull 21:701–704

    Google Scholar 

  • Mueller EA, Murphy DL, Sunderland T (1986) Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: evidence for a serotonin receptor mediated mechanism of action in humans. Psychopharmacology 89:388–391

    Google Scholar 

  • Murphy DL, Mueller EA, Garrick NA, Aulakh CS (1986) Use of serotonergic agents in the clinical assessment of central serotonin function. J Clin Psychiatry 47:9–15

    Google Scholar 

  • Pettibone DJ, Williams M (1984) Serotonin-releasing effects of substituted piperazines in vitro. Biochem Pharmacol 33:1531–1535

    Google Scholar 

  • Physicians' Desk Reference (1987) Medical Economics Company Inc, Oradell, NJ

  • Quattrone A, Schettini G, Annunziato L, Di Renzo G (1981) Pharmacological evidence of supersensivity of central serotonergic receptors involved in the control of prolactin secretion. Eur J Pharmacol 76:9–13

    Google Scholar 

  • Riblet LA, Taylor DP (1981) Pharmacology and neurochemistry of trazodone. J Clin Psychopharmacol 1:17S-22S

    Google Scholar 

  • Rokosz-Pelc A, Antkiewicz-Michaluk L, Vetulani J (1980) 5-Hydroxytryptamine-like properties of m-chlorophenylpiperazine: comparison with quipazine. J Pharm Pharmacol 32:220–222

    Google Scholar 

  • Samanin R, Mennini T, Ferraris A, Bendotti C, Borsini F (1980) Hyper-and hyposensitivity of central serotonin receptors: [H3] serotonin binding and functional studies in the rat. Brain Res 189:449–457

    Google Scholar 

  • Samanin R, Mennini T, Ferraris A, Bendotti C, Borsini F, Garattini S (1979) m-Chlorophenylpiperazine: a central serotonin agonist causing powerful anorexia in rats. Naunyn-Schmiedebergs Arch Pharmacol 308:159–163

    Google Scholar 

  • Sills MA, Lucki I, Frazer A (1985) Development of selective tolerance to the serotonin behavioral syndrome and suppression of locomotor activity after repeated administration of either 5-MeODMT or m-CPP. Life Sci 36:2463–2469

    Google Scholar 

  • Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC, Murphy DL (1987) Serotonergic responsivity in obsessive-compulsive disorder: comparison of patients and health controls. Arch Gen Psychiatry 44:946–951

    Google Scholar 

  • Zohar J, Insel TR, Zohar-Kadouch RC, Hill JL, Murphy DL (1988) Serotonergic responsivity in obsessive-compulsive disorder: effects of chronic clomipramine treatment. Arch Gen Psychiatry 45:167–172

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section on Clinical Neuropharmacology, Laboratory of Clinical Science, National Institute of Mental Health, NIH Clinical Center, 10-3D41, 9000 Rockville Pike, 20892, Bethesda, MD, USA

    Dennis L. Murphy, Edward A. Mueller, James L. Hill, Teresa J. Tolliver & Frederick M. Jacobsen

Authors
  1. Dennis L. Murphy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edward A. Mueller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James L. Hill
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Teresa J. Tolliver
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Frederick M. Jacobsen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Murphy, D.L., Mueller, E.A., Hill, J.L. et al. Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers. Psychopharmacology 98, 275–282 (1989). https://doi.org/10.1007/BF00444705

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00444705

Key words

Search

Navigation